Dieser IgE (Omalizumab Biosimilar) Antikörper ist unkonjugiert
Applikation
Flow Cytometry (FACS), In vivo Studies (in vivo)
Verwendungszweck
Omalizumab Biosimilar, Human IgE Monoclonal Antibody
Spezifität
The monoclonal antibody Omalizumab specifically binds to the human immunoglobulin E (IgE) free in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, omalizumab does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Produktmerkmale
Recombinant Humanized IgG1 Monoclonal Antibody.
Aufreinigung
Protein A affinity column
Reinheit
> 95% by SDS-PAGE under reducing conditions and HPLC.
Sterilität
0.2 μm filtered
Endotoxin-Niveau
< 1 EU per 1 mg of the protein by the LAL method.
Immunogen
The monoclonal antibody Omalizumab was produced in the Omalizumab biosimilar CHO stable cell line.
IgE antikoerper, immunoglobulin heavy constant epsilon antikoerper, IGHE antikoerper
Substanzklasse
Biosimilar
Hintergrund
Omalizumab is a humanized antibody used to reduce sensitivity to inhaled or ingested allergens, especially in the control of moderate to severe allergic asthma which does not respond to high doses of corticosteroids.
Immunoglobulin E (IgE) found in mammals only exists as monomers consisting of two heavy chains (ε chain) and two light chains, with the ε chain containing 4 Ig-like constant domains (Cε1-Cε4). In addition to immunity to parasites, IgE plays an essential role in type I hypersensitivity, which manifests various allergic diseases, and allergic conditions, such as anaphylactic reactions to certain drugs, bee stings, and antigen preparations used in specific desensitization immunotherapy.